Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers

Triple-negative breast cancers (TNBC) are among the most aggressive and heterogeneous cancers with a high propensity to invade, metastasize and relapse. Here, we demonstrate that the anticancer compound, AMPI-109, is selectively efficacious in inhibiting proliferation and inducing apoptosis of multi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gari, Hamid H., Gearheart, Christy M., Fosmire, Susan, DeGala, Gregory D., Fan, Zeying, Torkko, Kathleen C., Edgerton, Susan M., Lucia, M. Scott, Ray, Rahul, Thor, Ann D., Porter, Christopher C., Lambert, James R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941275/
https://www.ncbi.nlm.nih.gov/pubmed/26909599
http://dx.doi.org/10.18632/oncotarget.7462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941275/
https://www.ncbi.nlm.nih.gov/pubmed/26909599
http://dx.doi.org/10.18632/oncotarget.7462

Ejemplares similares